Awards 2023. 05. 23
CVinfo announced the "2022 CVAwards-Annual List". Innorna is honored to be among the "Top 10 Best Biomedical Investment Cases in China's Healthcare Industry in 2022".
"CVAwards" is a series of lists of China's private equity investment industry released by CVinfo as an independent third-party organization based on professional and objective industry data. The list is based on strict standards and is known for its professionalism, authority and rigor. Therefore, it is also known as the barometer of the domestic equity investment industry and is currently an important basis for many large institutional LPs to invest.
Innorna is committed to building an internationally leading mRNA and LNP technology platform and has been widely recognized by the industry and investment circles for its technical strength and innovation capabilities. In March 2022, Innorna announced the completion of US$120 million in Series B financing, with investment institutions including CDH Investments and China Renaissance, etc.
We are grateful for the recognition from ChinaVenture.com and the support of all investors along the way. We are convinced that Innorna will continue to build a diversity-oriented LNP delivery platform, continue to expand the boundaries of nucleic acid drug technology, and make unremitting efforts to accelerate the development and application of more new therapies.
